Relay Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$364.7M |
| Operating expenses | $318.1M | $382.5M | $398.5M | $300.7M | $367.7M |
| Cash from operations | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$74.4M |
| Capital expenditure | $410,000 | $2.0M | $4.1M | $9.1M | $3.5M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$77.9M |
| Impairments | — | $0 | $0 | $0 | $0 |
| Total assets | $621.3M | $871.3M | $844.0M | $1.1B | $1.0B |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M |
Shares outstanding 191.6M · Free float 63.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.